Thanksgiving break didn't slow down reviewers at the US FDA, as the agency came roaring out of the holiday with a batch of novel approvals.
Nods to Astellas Pharma Inc.'s Xospata (gilteritinib)and Catalyst Pharmaceuticals Inc
Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
